Precigen Reports $23.3 Million Revenue in Q1 2026, Driven by Papzimeos Launch

Precigen, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated total revenues of $23.3 million, a substantial increase from $1.3 million in the same period last year, primarily driven by the commercial launch of its FDA-approved immunotherapy, Papzimeos, which accounted for $21.6 million in product sales. This marks a pivotal transition for Precigen, which has moved from a development-stage to a commercial-stage company following the approval of Papzimeos for the treatment of recurrent respiratory papillomatosis (RRP).

The company's operating loss for the quarter was $6.0 million, a notable improvement compared to a loss of $22.6 million in the prior year, reflecting a 73.5% reduction. This improvement is attributed to the ramp-up in product sales and a decrease in research and development expenses, which fell by 46.2% to $5.6 million, as costs related to Papzimeos manufacturing transitioned from R&D to cost of goods sold following its approval. Selling, general, and administrative expenses increased by 70.3% to $21.0 million, driven by costs associated with the commercialization of Papzimeos.

Precigen's balance sheet as of March 31, 2026, showed total assets of $138.6 million, down from $155.5 million at the end of 2025. The decrease was primarily due to a reduction in cash and cash equivalents, which fell to $7.5 million from $30.2 million. The company also reported long-term debt of $93.5 million, reflecting its ongoing financing activities to support operations and product launches. The company’s accumulated deficit stood at $2.3 billion, indicating the financial challenges it has faced over the years.

In terms of operational metrics, Precigen's strategic focus on Papzimeos has led to a significant increase in customer engagement, with the company estimating approximately 27,000 adult patients in the U.S. living with RRP. The company has also initiated a marketing authorization application for Papzimeos in the European Union, further expanding its geographic reach. Additionally, Precigen's employee headcount has increased as it builds out its commercial capabilities to support the product launch.

Looking ahead, Precigen remains focused on the successful commercialization of Papzimeos and advancing its clinical pipeline, which includes several investigational therapies. The company anticipates that future revenues will increasingly depend on the sales of Papzimeos and the successful development of its proprietary programs. However, management has cautioned that achieving profitability will require ongoing efforts to generate sufficient revenue and may necessitate additional capital raises to support its operations and growth initiatives.